Nanoparticle-based delivery of self-amplifying RNA

[1] Lundstrom K(2019)Self-amplifying RNA virus vectors: clinical applications in cancer drug delivery Exp Opin Biol Ther 16 1027-undefined

[2] Lundstrom K(2018)Self-replicating RNA viruses for RNA therapeutics Molecules 23 E3310-undefined

[3] Henao-Restrepo AM(2017)Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!) Lancet. 389 505-undefined

[4] Camacho A(2008)Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa) J Clin Oncol 26 5538-undefined

[5] Longini IM(2017)Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma Leukemia. 31 2791-undefined

[6] Watson CH(2018)Latest development on RNA-based drugs and vaccines Future Sci OA 4 FSO300-undefined

[7] Edmunds WJ(2001)Synthesis and properties of mRNAs containing the novel ‘anti-reverse’ cap analogs 7-methyl(3′-O-methyl) GpppG and 7-methyl(33′-deoxy) GpppG RNA. 7 1486-undefined

[8] Egger M(2015)RNA-based vaccines in cancer immunotherapy J. Immunol Res. 2015 794528-undefined

[9] Galanis E(2002)Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Genome Biology 3 reviews0004.1-undefined

[10] Hartmann LC(2008)Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors Mol Ther. 16 1833-undefined

[1] Lundstrom K(2019)Self-amplifying RNA virus vectors: clinical applications in cancer drug delivery Exp Opin Biol Ther 16 1027-undefined

[2] Lundstrom K(2018)Self-replicating RNA viruses for RNA therapeutics Molecules 23 E3310-undefined

[3] Henao-Restrepo AM(2017)Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!) Lancet. 389 505-undefined

[4] Camacho A(2008)Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa) J Clin Oncol 26 5538-undefined

[5] Longini IM(2017)Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma Leukemia. 31 2791-undefined

[6] Watson CH(2018)Latest development on RNA-based drugs and vaccines Future Sci OA 4 FSO300-undefined

[7] Edmunds WJ(2001)Synthesis and properties of mRNAs containing the novel ‘anti-reverse’ cap analogs 7-methyl(3′-O-methyl) GpppG and 7-methyl(33′-deoxy) GpppG RNA. 7 1486-undefined

[8] Egger M(2015)RNA-based vaccines in cancer immunotherapy J. Immunol Res. 2015 794528-undefined

[9] Galanis E(2002)Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Genome Biology 3 reviews0004.1-undefined

[10] Hartmann LC(2008)Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors Mol Ther. 16 1833-undefined